Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases,
has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a …

At the end of 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2;
SARS-CoV-2) was detected in Wuhan, China, that spread rapidly around the world, with …

Omicron BA.2 Subvariant and Antiviral Agents The in vitro activity of monoclonal antibodies
and antiviral agents was assessed against the sublineages of the SARS-CoV-2 variant of …

Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Enterobacter cloacae is an important emerging pathogen, which sometime causes respiratory
infection, surgical site infection, urinary infection, sepsis, and outbreaks at neonatal units. …

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Monoclonal Antibody and Antiviral Activity against Omicron Investigators assessed the in
vitro activities of seven monoclonal antibodies and three antiviral drugs against Covid-19 …

A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
which caused a large respiratory outbreak in Wuhan, China in December 2019, is currently …

The recent emergence of SARS-CoV-2 Omicron (B.1.1.529 lineage) variants possessing
numerous mutations has raised concerns of decreased effectiveness of current vaccines, …

BACKGROUND Pseudomonas aeruginosa is responsible for a wide range of infections. In
immunocompromised patients with cancer, the emergence of multidrug resistant P. …